Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
Published Online: 2020-05-07
Journal: Trials•Publisher: Springer Science and Business Media LLC
Authors: Hiroki Hasegawa•Hiroshi Tada•Junji Tsurutani•Kazuhiro Araki•Kei Koizumi•Masahiro Kitada•Masato Takahashi•Norikazu Masuda•Satoshi Morita•Shigehira Saji•Shinji Ohno•Takayuki Kadoya•Toshimi Takano•Toshinari Yamashita•Tsuguo Iwatani•Tsutomu Iwasa•Yasuaki Sagara•Yasuyuki Kojima•Yoshinori Ito
